Items where authors include "Clarke, N.W."

Article

Parker, C.C. orcid.org/0000-0001-6512-124X, Petersen, P.M., Cook, A.D. orcid.org/0000-0003-4417-2632 et al. (55 more authors) (2024) Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047). Annals of Oncology, 35 (7). pp. 656-666. ISSN 0923-7534

Parker, C.C., James, N.D. orcid.org/0000-0002-7314-8204, Brawley, C.D. orcid.org/0000-0003-3641-278X et al. (43 more authors) (2022) Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLOS Medicine, 19 (6). e1003998. ISSN 1549-1277

Clarke, N.W., Ali, A., Ingleby, F.C. et al. (47 more authors) (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Annals of Oncology, 30 (12). pp. 1992-2003. ISSN 0923-7534

Hart, C.A., Scott, L.J., Bagley, S. et al. (3 more authors) (2002) Role of proteolytic enzymes in human prostate bone metastasis formation: in vivo and in vitro studies. British Journal of Cancer, 86 (7). pp. 1136-1142. ISSN 0007-0920

Proceedings Paper

Brown, J.E. orcid.org/0000-0003-4960-3032, Handforth, C., Walsh, J. orcid.org/0000-0002-7122-2650 et al. (5 more authors) (2019) 857P - Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial. In: Annals of Oncology. 44th ESMO Congress (ESMO 2019), 27 Sep - 01 Oct 2019, Barcelona, Spain. Elsevier BV , v334-v335.